Founded in 2001, Eddingpharm is a fast growing Chinese specialty pharmaceutical company, committed to bringing to the Chinese healthcare market high quality medicines from all over the world, providing patients with more treatment options and better opportunities for recovery. We promote collaboration and exchange between Chinese clinical experts and leading international medical research institutes, and provide academic support to Chinese clinical doctors.
Since its inception till the end of 2011, the company had established a highly integrated and well-managed sales network covering most of the major cities in China. Eddingpharm had grown into an organization with more than 700 employees in China, with a focuses on product sales and marketing, product registration, and the management of clinical trials. As of the end of December 2011, our sales and marketing, as well as products, covered more than 2,900 hospitals.
In March, 2012, Eddingpharm (U.S.) Company was set up in the U.S., along with a product development team based in Los Angeles, with a background of strong research and development capability. By engaging in coordination and communication with the world’s leading research and development institutions, the team is actively exploring opportunities to introduce innovative proprietary medicines in pre-clinical or clinical development phase into the Chinese market.
The company focuses on product development and sales and marketing in four therapeutic areas: clinical nutrition, oncology, antibiotics and respiratory system.
Eddingparm strives to build a product portfolio focused on the abovementioned four major therapeutic areas, through product in-licensing, joint venture, strategic alliance, exclusive distribution and other forms of collaboration with multinational pharmaceutical companies, overseas specialty pharmaceutical companies and the world’s leading research and development institutions.
Eddingpharm has established long-term partnerships with many multinational pharmaceutical companies and overseas specialty pharmaceutical companies, and has built a competitive product portfolio and pipeline in the four major therapeutic areas. At the same time, Eddingpharm is actively developing partnership with the world’s leading research and development organizations to secure the regional rights to innovative medicines and introduce them to the Chinese market